BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Golcadomide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Golcadomide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07763418-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Golcadomide: Phase 1 readout est. (NCT07763418)
DESCRIPTION:Golcadomide\, phase 1.\nStudy: A Study to Evaluate the Pharmaco
 kinetics and Safety of Golcadomide in Participants With Severe Renal Impai
 rment and End-Stage Renal Disease Compared With Participants With Normal R
 enal Function\nEstimated primary completion: 14 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07763418
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06209619-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Golcadomide: Phase 1 readout est. (NCT06209619)
DESCRIPTION:Golcadomide\, phase 1\, Large B-Cell Lymphoma.\nStudy: CC-99282
  + Rituximab Early Post CART for Non-Hodgkin's Lymphoma\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/golcadomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06209619
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06271057-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Golcadomide: Phase 2 readout est. (NCT06271057)
DESCRIPTION:Golcadomide\, phase 2\, Large B-Cell Lymphoma.\nStudy: Golcadom
 ide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With 
 High Risk of Relapse\nEstimated primary completion: 31 March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06271057
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03930953-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Golcadomide: Phase 1/2 readout est. (NCT03930953)
DESCRIPTION:Golcadomide\, phase 1/2.\nStudy: A Safety and Preliminary Effic
 acy Study of CC-99282\, Alone and in Combination With Anti-lymphoma Agents
  in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NH
 L)\nEstimated primary completion: 7 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/golcadomide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03930953
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06834373-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:Golcadomide: Phase 2 readout est. (NCT06834373)
DESCRIPTION:Golcadomide\, phase 2\, Large B-Cell Lymphoma.\nStudy: Golcadom
 ide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressiv
 e B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy\nEstimated primary
  completion: 10 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/golcadomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06834373
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917832-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Golcadomide: Phase 2 readout est. (NCT07917832)
DESCRIPTION:Golcadomide\, phase 2\, Large B-Cell Lymphoma.\nStudy: Smart 3:
  A Multi-Center Phase 2 Trial Of Golcadomide\, Glofitamab And Polatuzumab 
 Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/golcadomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07917832
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356129-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:Golcadomide: Phase 3 readout est. (NCT06356129)
DESCRIPTION:Golcadomide\, phase 3\, Large B-Cell Lymphoma.\nStudy: Study to
  Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placeb
 o Plus R-CHOP in Participants With Previously Untreated High-risk Large B-
 cell Lymphoma\nEstimated primary completion: 9 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06356129
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06090539-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Golcadomide: Phase 1/2 readout est. (NCT06090539)
DESCRIPTION:Golcadomide\, phase 1/2.\nStudy: A Study to Assess BMS-986458 A
 lone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory N
 on-Hodgkin Lymphomas\nEstimated primary completion: 28 October 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06090539
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269639-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Golcadomide: Phase 1/2 readout est. (NCT07269639)
DESCRIPTION:Golcadomide\, phase 1/2\, Large B-Cell Lymphoma.\nStudy: Golcad
 omide\, Poseltinib\, and Rituximab for Relapsed/Refractory Diffuse Large B
 -cell Lymphoma\nEstimated primary completion: 1 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07269639
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06108232-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Golcadomide: Phase 2 readout est. (NCT06108232)
DESCRIPTION:Golcadomide\, phase 2.\nStudy: Phase 2 Trial of Obinutuzumab an
 d CC-99282 for Patients With Previously Untreated High Tumor Burden Follic
 ular Lymphoma\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06108232
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05788081-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Golcadomide: Phase 2 readout est. (NCT05788081)
DESCRIPTION:Golcadomide\, phase 2.\nStudy: Treatment Of Newly-diagnosed Fol
 licular Lymphoma With CELMoD Golcadomide\, Rituximab +/- Nivolumab.\nEstim
 ated primary completion: 1 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/golcadomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05788081
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018752-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Golcadomide: Phase 1/2 readout est. (NCT07018752)
DESCRIPTION:Golcadomide\, phase 1/2.\nStudy: A Platform Trial Evaluating Ne
 w Drugs or Combination in R/R Peripheral T-cell Lymphomas\nEstimated prima
 ry completion: April 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/golcadomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07018752
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911502-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280424
DTEND;VALUE=DATE:20280425
SUMMARY:Golcadomide: Phase 3 readout est. (NCT06911502)
DESCRIPTION:Golcadomide\, phase 3.\nStudy: A Study to Compare the Efficacy 
 and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Inv
 estigator's Choice in Participants With Relapsed/Refractory Follicular Lym
 phoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK
 -4)\nEstimated primary completion: 24 April 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/golcadomide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06911502
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04884035-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Golcadomide: Phase 1 readout est. (NCT04884035)
DESCRIPTION:Golcadomide\, phase 1.\nStudy: Study of Safety and Efficacy of 
 Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma\nE
 stimated primary completion: 1 December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/golcadomide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04884035
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608731-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Golcadomide: Phase 1 readout est. (NCT07608731)
DESCRIPTION:Golcadomide\, phase 1\, Large B-Cell Lymphoma.\nStudy: Golcadom
 ide With Pemetrexed\, Rituximab\, and Dexamethasone for Relapsed and Refra
 ctory CNS Lymphomas\nEstimated primary completion: April 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07608731
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05169515-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Golcadomide: Phase 1 readout est. (NCT05169515)
DESCRIPTION:Golcadomide\, phase 1.\nStudy: A Study Evaluating the Safety\, 
 Pharmacokinetics\, and Efficacy of Mosunetuzumab or Glofitamab in Combinat
 ion With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Ly
 mphoma\nEstimated primary completion: 30 April 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/golcadomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05169515
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06835530-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Golcadomide: Phase 2 readout est. (NCT06835530)
DESCRIPTION:Golcadomide\, phase 2.\nStudy: A Combination of Rituximab and C
 C-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large 
 B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessm
 ent (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)\nEsti
 mated primary completion: April 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/golcadomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06835530
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578077-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20300421
DTEND;VALUE=DATE:20300422
SUMMARY:Golcadomide: Phase 1/2 readout est. (NCT07578077)
DESCRIPTION:Golcadomide\, phase 1/2.\nStudy: Golcadomide in Combination Wit
 h Rituximab for the Treatment of Patients With Relapsed or Refractory Mant
 le Cell Lymphoma\nEstimated primary completion: 21 April 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07578077
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05283720-11182@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Golcadomide: Phase 2 readout est. (NCT05283720)
DESCRIPTION:Golcadomide\, phase 2.\nStudy: A Study to Evaluate Adverse Even
 ts and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Comb
 ination With Oral and Intravenous Anti-Neoplastic Agents in Adult Particip
 ants With Non-Hodgkin Lymphoma\nEstimated primary completion: November 203
 2. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/golcadomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05283720
URL:https://assetmemo.bio/drug/golcadomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
